Journal profile · Oncology
Cancer Treatment Reviews
ISSN 0305-7372 · eISSN 1532-1967 · W.B. Saunders Ltd · ENGLAND · Quarterly · Founded 1974
Cancer Treatment Reviews: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 10.47; hybrid open access; APC about USD 4,910; median 60 days to acceptance (99 articles, last 24 months); community-reported acceptance: about 25%; 136 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Treatment Reviews is published by W.B. Saunders Ltd and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Treatment and Pharmacology, Human auditory perception and evaluation and Diverse Scientific and Economic Studies, together about 20.2% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Treatment Reviews is an international journal that provides state of the art, authoritative review articles to the clinician and researcher to keep them abreast of modern concepts and the latest developments in cancer treatment research.Journal of Cancer Treatment Reviews' Inclusion and Diversity PledgeThis journal pledges to maintain diversity on the editorial team. This sits within Elsevier's broader ongoing inclusion & diversity efforts. Equity and inclusion in publishing is critically important for scientific excellence and innovation. We believe passionately in the power of an inclusive publishing environment, not only to do what is right, but to enrich, strengthen and advance us all.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Andrés CervantesPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United Kingdom 8, United States 6, Italy 6, Hong Kong, China 4, Germany 3 (50 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Treatment and PharmacologyMedicine7.4%
- Human auditory perception and evaluationEngineering6.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance6.4%
- Lung Cancer Treatments and MutationsMedicine6%
- Educational Robotics and EngineeringComputer Science6%
- HER2/EGFR in Cancer ResearchMedicine5.8%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.6%
- Lung Cancer Research StudiesMedicine5.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 10.47LetPub ·
- Impact factor (publisher)
- 10.6Publisher website ·
- CiteScore 2026-06
- 17.7LetPub ·
- CiteScore (publisher)
- 17.7Publisher website ·
- SJR 2026-06
- 3.75LetPub ·
- SNIP 2026-06
- 2.66LetPub ·
- h-index
- 116LetPub ·
- h-index
- 206OpenAlex ·
- i10-index
- 2,598OpenAlex ·
- 2-year mean citedness
- 10.3OpenAlex ·
- Self-citation rate
- 0.9%LetPub ·
- Share of gold OA articles
- 37.12%LetPub ·
Volume
- Articles per year
- 118LetPub ·
Articles by year OpenAlex count · 4,058 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 87 | 40 | 80 |
| 2025 | 136 | 81 | 1,211 |
| 2024 | 132 | 78 | 2,366 |
| 2023 | 107 | 68 | 3,173 |
| 2022 | 110 | 55 | 5,134 |
| 2021 | 121 | 74 | 6,192 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
60 daysMedian, submission to acceptance · P25–P75 42 days – 85 days
- Acceptance to online
- median 2 days (99 articles)
- Submission to online
- median 63 days
- Sample
- 99 articles with submission and acceptance dates (245 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 monthsLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 34 daysPublisher website ·
- Submission to acceptance
- 64 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,910 / EUR 4,590 / GBP 3,930 / JPY 608,990 | — | — | |
| Publisher website | USD 5,330 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 5,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Required
Article types accepted11, with length limits
- anti-tumour treatment• Anti-tumour TreatmentLength not stated
- comments on controversy• Comments on ControversyLength not stated
- complications of treatment• Complications of TreatmentLength not stated
- general and supportive care• General and Supportive CareLength not stated
- laboratory-clinic interface• Laboratory-Clinic InterfaceLength not stated
- meta-analysisAuthors will be asked to assign their contribution to one of the following areas:• Comments on Controversy• Tumour Review• Anti-tumour Treatment• New Drugs• Com…main text ≤ 5,000 words
- new drugs• New DrugsLength not stated
- reviewAuthors will be asked to assign their contribution to one of the following areas:• Comments on Controversy• Tumour Review• Anti-tumour Treatment• New Drugs• Com…Length not stated
- review articleAuthors will be asked to assign their contribution to one of the following areas:• Comments on Controversy• Tumour Review• Anti-tumour Treatment• New Drugs• Com…Length not stated
- systematic or meta-analysis studies• Systematic or Meta-analysis StudiesLength not stated
- tumour review• Tumour ReviewLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
5000 word limit and 6 figures/tables for review articles Model summary
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, not counted as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- W.B. Saunders Ltd
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 1974
- ISSN
- 0305-7372
- Electronic ISSN
- 1532-1967
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Treatment Reviews
What CAS zone is Cancer Treatment Reviews in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Treatment Reviews is in Zone 1 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Treatment Reviews?
The latest impact factor listed by LetPub is 10.47; CiteScore 17.7, h-index 206.
How long does peer review take at Cancer Treatment Reviews?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 60 days (interquartile range 42–85 days); authors report an average review time of about 6 months; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Treatment Reviews?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 5,000 words; Reference style: Numbered, in order of citation; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Treatment Reviews based?
Of the 50 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United Kingdom (8), United States (6) and Italy (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Treatment Reviews?
According to LetPub and DOAJ records, Cancer Treatment Reviews is indexed in SCIE and Scopus.
Is Cancer Treatment Reviews open access, and what is the APC?
Cancer Treatment Reviews is a hybrid journal. For open-access publication: APC about USD 4,910.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .